Explore 3 Stock Ideas & Industry Insights Download Free Report

Positron Corp

Company price
1.57 USD -0.04 ( 2.48%)
Last update at 2026-11-19T20:25:00Z
VOLUME
200
Market Cap
58.47M

Momentum Score

…

Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.57
Low
1.60
High
52 Week Price Range
1.27
Low
2.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.61
Dividend Yield
-
Revenue TTM
0.44M
Revenue Per Share
0.01
Gross Profit TTM
-2.37M
Debt / Equity
1.35
ROE
-2694.31%
Net Debt
-0.57M
ROCE
-657.18%
Diluted EPS TTM
-0.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.60M -2.39M -1.64M -2.86M -0.60M
Net income -10.60M -2.39M -1.64M -2.86M -0.60M
Selling general administrative 8.38M 1.86M - - -
Gross profit -2.11M -0.34M -0.35M -0.08M 0.13M
Reconciled depreciation 0.05M 0.04M - - -
Ebit -10.50M -2.21M -1.49M -2.81M -0.60M
Ebitda -10.44M -2.18M -1.45M -2.77M -0.57M
Depreciation and amortization 0.05M 0.04M 0.04M 0.04M 0.03M
Operating income -10.50M -2.21M -1.36M -2.68M -0.76M
Other operating expenses 10.96M 2.80M 2.10M 3.41M 1.65M
Interest expense 0.13M 0.17M 0.28M 0.05M -
Interest income 0.04M 0.00M - - -
Net interest income -0.09M -0.17M - - -
Income tax expense - - 0.00M -0.00M 0.00M
Total revenue 0.46M 0.59M 0.73M 0.73M 0.88M
Total operating expenses 8.38M 1.87M 1.01M 2.60M 0.90M
Cost of revenue 2.58M 0.93M 1.09M 0.81M 0.75M
Total other income expense net -0.10M -0.17M -0.28M -0.18M 0.17M
Net income from continuing ops -10.60M -2.38M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4.00M 1.80M 1.77M 1.77M 1.96M
Other current assets 0.13M 0.01M 0.00M 0.00M 0.00M
Total liab 2.56M 2.21M 2.03M 1.89M 0.34M
Total stockholder equity 1.44M -0.41M -0.26M -0.12M 1.62M
Other current liab - - 0.00M - -
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.63M - - -
Retained earnings -144.94M -134.09M -131.70M -129.31M -127.00M
Other assets - 0.00M 0.00M - 0.00M
Cash 2.52M 0.07M 0.10M 0.07M 1.41M
Total current liabilities 2.40M 2.19M 1.98M 1.83M 0.34M
Current deferred revenue 0.12M 0.07M 0.02M 0.02M 0.02M
Net debt -0.57M 1.73M 1.69M 1.47M -1.10M
Short term debt 1.79M 1.78M 1.74M 1.49M 0.32M
Short long term debt 1.76M 2.01M - - -
Short long term debt total 1.95M 1.80M 1.79M 1.54M 0.32M
Other stockholder equity 146.38M 133.05M 130.82M 129.31M 128.00M
Total current assets 3.34M 1.35M 1.38M 1.34M 1.64M
Net receivables 0.01M 0.02M 0.02M 0.01M 0.02M
Inventory 0.68M 1.26M 1.26M 1.26M 0.20M
Accounts payable 0.49M 0.34M 0.21M 0.33M 0.01M
Accumulated other comprehensive income 0.00M - -0.00M -0.00M -0.00M
Non currrent assets other 0.37M 0.37M 0.27M 0.28M 0.21M
Non current assets total 0.66M 0.45M 0.39M 0.43M 0.33M
Capital lease obligations 0.18M 0.04M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities -0.10M - - - -0.09M
Net borrowings -0.25M 0.30M - - -
Total cash from financing activities 7.25M 1.70M 1.62M 1.20M 2.10M
Net income -10.60M -2.39M -1.64M -2.86M -0.60M
Change in cash 2.45M -0.03M 0.03M -1.34M 1.39M
Begin period cash flow 0.07M 0.10M 0.07M 1.41M 0.03M
End period cash flow 2.52M 0.07M 0.10M 0.07M 1.41M
Total cash from operating activities -4.70M -1.73M -1.60M -2.54M -0.62M
Issuance of capital stock 10.00M 1.40M - - -
Depreciation 0.05M 0.04M 0.04M 0.04M 0.03M
Other cashflows from investing activities - - -0.00M - -
Change to inventory - - - -1.26M -0.08M
Change to account receivables 0.01M 0.01M -0.01M 0.01M 0.02M
Sale purchase of stock -2.50M 0.00M - - -
Other cashflows from financing activities - - -0.25M - -0.09M
Capital expenditures 0.10M 0.00M 0.00M 0.00M 0.09M
Change in working capital 0.11M 0.05M -0.13M -1.00M -0.10M
Stock based compensation 4.98M 0.00M - - -
Other non cash items 5.73M 0.56M 0.13M 1.28M 0.05M
Free cash flow -4.80M -1.73M -1.60M -2.54M -0.71M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
POSC
Positron Corp
-0.04
2.48%
1.57 - 103.09 131.43 370.36 134.98 -4.12
ABT
Abbott Laboratories
-0.10
0.10%
103.87 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-
-%
100.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-0.13
0.04%
313.08 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
0.64
1.35%
48.14 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Positron Corp

Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.

3784 Commerce Court, North Tonawanda, NY, United States, 14120

727 287 2800

10

Name Title Year Born
Mr. Adel Abdullah Pres & Director NA
Mr. Adel Abdullah President & Chairman 1974
Mr. Aaron Hargrave Vice President 1986

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…